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SUMMARY 
The increasing prevalence of obesity markedly triggers the current epidemics of type 2 
diabetes (T2DM). Abdominal adiposity, a feature of ectopic fat syndrome, is associated with 
silent inflammation, abnormal hormone secretion and various metabolic disturbances that 
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contribute to insulin resistance and insulin secretory defect, resulting in T2DM, and induce a 
toxic pattern leading to cardiovascular disease, liver pathologies and cancer. Despite the 
importance of weight control strategies in the prevention and management of T2DM, long-
term results are generally disappointing with lifestyle or drug interventions. Furthermore, 
most of the classical glucose-lowering agents are accompanied by weight gain rendering even 
more challenging the management of most overweight/obese individuals with T2DM. Many 
anti-obesity pharmacological agents targeting central control of appetite were withdrawn from 
the market because of safety concern. The gastrointestinal lipase inhibitor orlistat remained 
the only anti-obesity medication available until the recent launch (US but not Europe) of 
phentermine-topiramate CR and lorcaserin. The recent better knowledge of bodyweight 
regulation opens new perspectives with the potential use of peptides derived from the gut or 
the adipose tissue. Most probably, combination therapy would be necessary to avoid 
compensatory mechanisms and potentiate initial weight loss while avoiding weight regain. 
New glucose-lowering therapies, especially glucagon-like peptide-1 receptor agonists and 
sodium glucose cotransporter-2 inhibitors, offer advantages over traditional antidiabetic 
agents by promoting weight loss while improving glucose control. . The present review will 
explore the overlapping pathophysiology and also how the various therapies can, alone or in 
combination, combat the 'dual burden' of obesity and T2DM. 
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Introduction  
The dramatic rise of the twin epidemics, type 2 diabetes (T2DM) and obesity, is 
associated with increased mortality and morbidity and represents  one of the most important 
public health challenges worldwide1.T2DM is a complex disease where  genetic and 
epigenetic factors interact with a toxic environment that promotes the development of 
obesity2. Environmental risk factors include the consumption of high-calorie, high-fat foods, 
inadequate physical activity and recently proposed alternative mechanisms (see panel), 
creating a chronic energy imbalance3. Especially abdominal adiposity is associated with 
markedly increasing risk for T2DM, and overall 80% of people with T2DM are overweight or 
obese. Striking parallel increases in the prevalence of obesity and T2DM reflect the 
importance of body fatness as a contributing factor to diabetes incidence and complications4.  
Furthermore, adipose tissue is as an active endocrine and immune organ whose dysfunction 
(adiposopathy or "sick fat") is promoted by excessive caloric balance. Thus, targeting 
adiposopathy and not only body weight excess should be considered as a main objective in the 
management of the obese patient with T2DM5.   
Both obesity and T2DM carry with them many medical complications, especially 
cardiovascular (CV) disease6, substantially increasing global medical costs1. Aggressive 
treatment, in particular preventing weight gain and ideally facilitating weight reduction, can 
minimize and reduce diabetes-associated complications7. However, weight loss and 
maintenance are challenging in the obese population without diabetes, even more in obese 
people with T2DM8. 
The close link between T2DM and excess body weight highlights the need to consider 
the weight effects of different treatment regimens, besides their effects on glucose 
homeostasis9. A paradigm shift from a glucocentric to a weight-centric management of T2DM 
may be proposed, emphasising the urgent need for new treatment strategies10, 11.  Some 
glucose-lowering drugs cause weight loss and some (albeit fewer) anti-obesity drugs improve 
glucose tolerance; thus, the present review will explore the overlapping pathophysiology of 
obesity and T2DM and also how the various therapies can, alone or in combination, combat 
the “dual burden”. We will focus on lifestyle and drug therapy, whereas the marked success of 
bariatric/metabolic surgery in combating the dual burden obesity-T2DM has been covered 
elsewhere12. 
 




Main contributors to the pathophysiology of obesity and T2DM 
- Genetic predisposition and unhealthy lifestyle (sedentarity. overeating) 
- Adipose tissue dysfunction leading to ectopic fat deposition 
- Excess visceral fat (“adiposopathy” associated with silent inflammation) 
- Insulin resistance leading to β-cell burden and progressive B-cell 
dysfunction/defect 
- Dysfunction in neurohumoral pathways (interrelationships between brain, 
endocrine pancreas, adipose tissue and gastrointestinal tract) 
- Potential role of environmental pollutants  




Search strategy and selection criteria 
We searched Medline, PubMed, the Cochrane library, and Google Scholar for mainly 
original research articles published between 1973 and November 2013, and focused on the 
dual treatment of obesity and T2DM. The main search terms used were “obesity”, “type 2 
diabetes”,  “glucose-lowering”, “antidiabetic”, “anti-obesity”, “weight loss”  We identified 
full-text papers without imposing any language restriction. Reference lists of original studies, 
narrative reviews and previous systematic reviews and meta-analyses were also carefully 
examined. Criteria used to include or exclude studies were randomised controlled trials and 
meta-analyses (see restrictions in the legends of the various tables). 
 
Complex interplay between obesity and T2DM  
 Impact of weight changes on T2DM 
 The excess risk for diabetes with even modest weight gain is substantial and absolute 
weight gain throughout adulthood is a significant independent risk factor for T2DM7. 
Intentional weight loss is associated with reduced insulin resistance and a subsequent 
reduction in glucolipotoxicity, improving overall glucose homeostasis4, 13. In both the Finnish 
and US Diabetes Prevention Program (DPP), weight loss gradually reduces the risk of 
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diabetes, and even modest weight loss can significantly reduce the incidence of T2DM, an 
effect persisting in the long-term14, 15. In the recent Look AHEAD (Action for Health in 
Diabetes) trial in overweight/obese patients with T2DM, weight loss was greater in the 
intensive lifestyle intervention group than in the control group throughout the study, and this 
was accompanied by greater reductions in HbA1c, allowing a lower use of  insulin in the 
intervention group than in the control group16. 
 
 
 Impact of glucose control on body weight regulation  
Reaching and maintaining acceptable body weight is more difficult in 
overweight/obese patients with T2DM17. Among other factors, hyperinsulinaemia may 
contribute to this phenomenon via the antilipolytic and anabolic effects of the hormone8. For a 
given weight loss during a very-low calorie diet, the decrease in adiposity per unit weight loss 
was attenuated in T2DM subjects, possibly due to the anti-lipolytic effect of 
hyperinsulinaemia18. Furthermore, improvement in glucose control results in decreased 
glucosuria and thereby limitation of energy wasting8. Thereby, losing weight and fat mass is 
challenging in patients with T2DM7, 19.  
While reduction of hyperglycaemia remains the foremost goal in the pharmacological 
treatment of T2DM, the avoidance of weight gain may be a clinically important secondary 
goal20. Except metformin, traditional glucose-lowering medications for 
T2DM (sulphonylureas, glitazones, insulin) can further increase weight in overweight/obese 
patients21 and this may undermine the benefits of improved glycaemic control 7. Even if a link 
between drug-induced weight gain and increased CV risk has not been established yet, 
pharmacological approaches that do not cause weight gain or promote weight loss, for 
example those that target the gut (incretin-based therapies)22 or the kidneys (sodium glucose 
cotransporter-2 or SGLT-2 inhibitors)23, may represent a valuable alternative in selected 
patients despite their higher cost 21.  
 
 Comorbidities shared and magnified by both obesity and diabetes 
Adipose tissue releases many bioactive mediators that influence body weight 
homeostasis, insulin resistance, lipids, blood pressure, coagulation, fibrinolysis and 
inflammation, which together contribute to oxidative stress, endothelial dysfunction and 
atherosclerosis6. Therefore, obesity is not only a major risk factor for the development 
of T2DM but also predisposes individuals to co-morbidities including hypertension, 
   6
dyslipidaemia and sleep apnoea. Together, obesity and its comorbid conditions increase the 
risk for CV disease, the major cause of morbidity and mortality in T2DM [see below]. 
Conversely, moderate weight loss (>5% initial bodyweight), which has been associated with 
improvements in glycaemic parameters, also reduces the presence of other comorbidities, 
including dyslipidaemia and hypertension, culminating in a reduced risk of CV disease24.  For 
all new medications developed as anti-obesity drugs (or as antidiabetic agents), their impact 
on CV risk factors (and ideally CV outcomes) is important to analyze, besides their specific 
weight-loss or glucose-lowering benefits5.  
Nonalcoholic fatty liver disease (NAFLD) is also commonly associated with 
(abdominal) adiposity, dyslipidaemia and insulin resistance. T2DM is an additional risk factor 
for progressive liver disease and liver-related death in patients with NAFLD. Nonalcoholic 
steatohepatitis (NASH) is present in approximately 10% of patients with T2DM and is 
associated with an increased risk for the development of cirrhosis, hepatocellular carcinoma 
and liver-related death25. 
There is a growing body of evidence to support a connection 
between T2DM, obesity and cancer26. Multiple meta-analyses of epidemiological data show 
that people with T2DM are at increased risk of developing many different types of cancers, 
along with an increased risk of cancer mortality. A number of common risk factors, 
including obesity, may be behind the association between diabetes and cancer. Abdominal 
adiposity, as part of the ectopic fat syndrome, has been shown to play a role in creating insulin 
resistance and a systemic pro-inflammatory environment, which could result in the 
development of both diabetes and cancer26.  
 
Obstructive sleep apnoea  is a highly prevalent condition often associated with 
central obesity, which could contribute to worsen insulin resistance and lead to impaired 
glucose tolerance and T2DM27. Improvement of sleep apnoea with weight reduction can also 
improve insulin sensitivity and glucose profile.  
 
  
As discussed, obesity is well known to worsen CV complications associated with 
diabetes 5, 6, but it may also be the case for microangiopathy. Obesity is an independent risk 
factor for kidney alterations, since it is associated with an increased risk of albuminuria and 
glomerulosclerosis, and worsens the course of chronic kidney disease28. T2DM persons with 
higher body mass index (BMI) and larger neck circumference are more likely to have diabetic 
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retinopathy and more severe stages of diabetic retinopathy29. Finally, CV autonomic 
neuropathy is common in persons with diabetes, and central obesity seems to play an 
important role in the early pathogenesis of this complication too30. 
Thus, targeting both obesity and diabetes will reduce the incidence and severity of 
most of these comorbid conditions, increasing patient’s quality of life and lessening strain on 
health-care systems. 
 
Pathophysiology and common therapeutic pathways  
The common pathophysiology of obesity and T2DM is rather complex (Figure 1) and  
whether there is a “common soil”, or whether obesity simply leads to T2DM, remains an open 
question. Genetic predisposition, epigenetic factors (programming in early life) and 
environmental exposure play a major role in the development of both obesity and T2DM31, 32. 
Even if epigenetic factors raised much interest in recent years, there is limited data to suggest 
that currently available interventions (lifestyle, drugs) may cause epigenetic modifications32. 
Overall, T2DM develops in obese people because of inadequate islet β-cell and adipose-tissue 
responses to chronic fuel excess, which results in so-called nutrient spillover, and metabolic 
stress that damages multiple organs3, 13, 33. Furthermore, environmental pollutants34 and 
specific bacterial intestinal colonization35 have recently been proposed as additional risk 
factors for obesity, β-cell dysfunction and T2DM development. Thus, reversal of 
overnutrition (contributing to weight loss), lessening of adipose tissue disturbances and 
protection/ healing of the β cells should be treatment priorities5, 31. 
Increasing evidence suggests that dysregulation in complex neurophysiological 
pathways (including hormonal secretions from adipocytes, pancreatic islets and the 
gastrointestinal tract) contributes to pathogenesis of obesity and T2DM (Figure 1). For 
instance, the neurohormonal control of body weight involves a complex interplay between 
long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin) 37.  
The adipocyte-secreted leptin is known as a key appetite-regulating hormone, which effects 
on food intake, energy expenditure and behavior. Furthermore, leptin is not only a key player 
in controlling bodyweight but also affects the insulin-glucose axis. Dysfunction of the adipo-
insular crosstalk plays a role in the development of hyperinsulinaemia and T2DM36. Amylin, 
an hormone co-secreted with insulin, exerts effects that complement those of insulin to 
regulate blood glucose concentrations, while it contributes to avoid weight gain and even 
promote weight loss37. Incretins, which are gut-derived hormones released in response to 
nutrient ingestion, may be perturbed in obesity and T2DM38. For example, glucagon-like 
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peptide-1 (GLP-1) can reduce food intake, via both central (hypothalamus) and peripheral 
(stomach) actions, but also markedly enhances insulin secretion, an effect that is essential in 
limiting postprandial hyperglycaemia38. These observations open new prospects for a better 
integrative management of obesity and T2DM22. 
 
Clinical challenges   
The main clinical objectives in tackling the dual burden of obesity and T2DM may be 
: (i) in normoglycaemic overweight/obese patients, the primary prevention of T2DM, 
especially in patients at higher risk (those with impaired glucose tolerance for instance); (ii) in 
overweight/obese patients with T2DM, the reduction in bodyweight to facilitate glucose 
control (and reduce other risk factors) or at least avoid further weight gain; and (iii) the 
selection of effective treatments of both obesity and T2DM in the same patient while reducing 
associated CV risk factors and improving quality of life and life expectancy19. Similar to 
lifestyle changes, which positively influence both body weight and glucose control (Figure 2), 
other therapeutic interventions, especially pharmacological approaches, should ideally target 
both body weight and glucose regulation in an integrative approach8, 19. However, long-term 
head-to-head comparisons of the various treatment options on overall patient’s prognosis are 
still lacking for most approaches. In particular, these  is an urgent need for more data on 
young people, in whom the prevalence of obesity and type 2 diabetes is increasing.  
Blood glucose control becomes increasingly challenging in the obese patient with 
T2DM after failure of metformin monotherapy (a glucose-lowering medication that does not 
induce weight gain or hypoglycaemia)11, 19. Attempts to reach fasting/postprandial glucose or 
glycated haemoglobin (HbA1c) targets with other therapies can lead to a higher risk of 
hypoglycaemia and/or weight gain, which can worsen overall prognosis8. Fear of 
hypoglycaemia and/or weight gain might favour physician’s therapeutic inertia and reduce 
patient’s compliance, contributing to the fact that targets are largely unmet worldwide. 
Relatively recently developed incretin-based therapies now offer some benefits regarding both 
weight changes and risk of hypoglycaemia22. Nevertheless, additional new strategies with low 
risk of hypoglycaemia and weight gain (and if possible with some weight loss) should be 
developed to better control glucose; ideally, such strategies should also improve also other 
CV risk factors10, 22. 
Worsening trends in obesity and T2DM raise a serious conundrum : how can blood 
glucose, blood pressure, and lipids be controlled when so many antidiabetic agents cause 
weight gain and thereby exacerbate CV risk factors ? Thus, a clear need exists for clinicians to 
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understand the risks and benefits of different therapeutic options in order to minimize CV risk 
in obese patients with T2DM11. In the next sections, we discuss evidence underlying 
treatments for obesity and diabetes that can help to inform the clinician as to the most 
appropriate strategy (lifestyle, monotherapy, or combination therapy) for each individual 
patient. 
 
Lifestyle intervention in the management of obesity and T2DM 
Diet alone 
Obesity is mainly caused by an excess of caloric intake in relation to energy 
expenditure3 so its treatment should primarily focus on healthy diet and increased physical 
activity, especially in presence of T2DM (Figure 2)39. Implementing and maintaining the 
lifestyle changes associated with weight loss can, however, be challenging for many 
patients24. Various weight-loss strategies with follow-up for at least 6 months have been 
evaluated in people with T2DM with variable results40. 
Nutritional interventions are most effective in promoting initial weight loss. 
Furthermore, energy restriction will improve glycaemic control within days of initiation, 
independent of weight loss. However, the net improvement of glucose profile is usually small 
1 year after weight loss. Very-low-calorie diets lead to better initial weight loss and glycaemic 
control but yield no better long-term results than more moderate energy restriction treatment.  
Weight loss seems to be mediated via changes in energy intakes rather than diet 
composition41. Similarly, diet composition has little effect on glycaemic control independent 
of total calories40. However, recent data suggest that prebiotic and probiotic approaches may 
target gut microbiome and thereby improve host metabolism42.  
 
Physical activity alone 
Exercise training that consisted of aerobic exercise, resistance training, or both 
combined significantly reduced HbA1c in patients with T2DM43, but no significantly greater 
change in BMI was found when exercise groups were compared with control groups. 
Importantly, BMI might not be a very relevant measure in exercise studies: exercise can 
increase muscle mass while decreasing fat mass (a good thing for patient health), such 
changes are not necessarily reflected by a change in BMI. In another study, a 12-week aerobic 
exercise programme, without hypocaloric diet, reduced visceral adipose tissue, an effect that 
may improve overall metabolic profile44.  
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Diet and physical activity combination 
Lifestyle combining healthy hypocaloric diet and physical activity is the mainstay of 
management to improve the metabolic profile of overweight/obese individuals with 
prediabetes or T2DM. The clinical effectiveness of such an approach has been established 
from randomised controlled trials (RCTs) of structured interventions14, 15. However, 
translation into routine practice has generally less effect on T2DM risk reduction45. In a meta-
analysis of randomised controlled trials, HbA1c changes in patients with T2DM corresponded 
to those in bodyweight and both changes were overall rather small46. However, while the 
overall improvements are limited from a population standpoint, some individuals may achieve 
substantial improvements in multiple metabolic parameters. 
It must also be mentioned that lifestyle might not be sufficient to reduce CV risk in patients 
with T2DM. The recent Look Ahead trial examined whether an intensive lifestyle intervention 
for weight loss would decrease CV morbidity and mortality among overweight/obese patients 
with T2DM. After a median follow-up of 9.6 years and despite significant improvements in 
bodyweight and various CV risk factors and a partial remission of T2DM47, there was no 
difference in the primary outcome, a composite of death from CV causes, nonfatal myocardial 
infarction, nonfatal stroke, or hospitalization for angina16. An insufficient weight reduction in 
the intervention group versus the control group or progressive better medical management of 
CV risk factors in routine medical care might be possible explanations for the lack of 
significant difference in the rate of CV events between groups16.   
To date, no controlled study is available showing that lifestyle intervention alone is 
able to reduce the incidence and the severity of diabetes-related complications.  
 
Anti-obesity agents with positive effects on diabetes 
Although the obesity epidemic is constantly expanding at very high costs for health 
care systems, the currently available options for the pharmacotherapy of obesity are very 
limited because of a poor efficacy/safety profile of the majority of the antiobesity drugs 
developed up to now. Nevertheless, several antiobesity drugs have demonstrated potential in 
the prevention and management of T2DM48, 49, although the long-term health benefits remain 
unclear.  
Most medications used as anti-obesity agents were withdrawn because of safety 
issues50.  Nevertheless these drugs supported the proof-of-concept that pharmacological 
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approaches to promote weight loss may contribute to improve blood glucose control and 
attenuate other CV risk factors in patients with T2DM, and that part of these metabolic effects 
occur independent of weight loss. This was first the case for fenfluramine and its stereoisomer 
dexfenfluramine although these drugs, mainly acting by releasing serotonin, were only 
evaluated in small-size short-term clinical trials in patients with T2DM,48 and are not 
reviewed here. 
In 2012, the US Food and Drug Administration (FDA) approved two new medications, 
lorcaserin and phentermine-topiramate ER, which may help in combating the dual burden of 
obesity and T2DM 24, 51. However, these two medications did not receive approval from the 
European Medicine Agency (EMA) so that it seems that the overall political environment 
against anti-obesity drug therapy is different in the US and in Europe52. Although head-to-
head comparison trials are not available, lorcaserin is likely less effective but better tolerated 
than phentermine/topiramate ER in obese patients with or without T2DM. CV outcome data 
will be invaluable in determining the place of both drugs in the therapy in overweight/obese 
patients with T2DM53.  
 
Sibutramine 
Sibutramine inhibits the reuptake of both norepinephrine and serotonin. It induces 
dose-dependent weight loss in overweight/obese patients, with improvement of some CV risk 
factors, especially lipid profile (increased HDL cholesterol)54 and glucose profile55. In obese 
subjects with T2DM56, the reduction in bodyweight, waist circumference, fasting blood 
glucose and HbA1c levels were significantly greater after sibutramine (10-20 mg/day) than 
after placebo (see references in Table 1, upper part). However, the overall effect size on 
HbA1c was rather modest (-0.28% , 95% CI 0.13 to 0.42; P =0.0002), with some heterogeneity 
among studies57. Because sibutramine may increase heart rate and blood pressure, concern has 
been raised about its CV safety58. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial 
in overweight/obese subjects with preexisting CV disease, T2DM, or both (84% with T2DM) 
showed a significantly higher risk of a primary CV outcome event in the sibutramine group 
than in the placebo group59. However, greater weight loss was associated with reduced overall 
CV risk in both groups60.Sibutramine was withdrawn from the market due to an uncertain 
benefit-risk balance, even in patients with T2DM.  
 
  Rimonabant 
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Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and 
improves CV and metabolic risk factors in non-diabetic overweight/obese patients61. 
Rimonabant 20 mg/day produced a clinically meaningful reduction in bodyweight and 
improved HbA1c and various CV and metabolic risk factors in patients with T2DM 
inadequately controlled with various glucose-lowering therapies (see references in table 1, 
lower part). In a pooled efficacy analysis, rimonabant produced weight loss and significant 
improvements in multiple cardiometabolic risk factors such as waist circumference, HbA1c, 
HDL cholesterol, triglycerides and blood pressure, and some of these effects were partly 
independent of weight loss62. However, rimonabant increased the risk of psychiatric adverse 
events63. The CV outcome study CRESCENDO (Rimonabant for prevention of cardiovascular 
events) was stopped prematurely because of a higher risk of suicide in the rimonabant 20 mg 
group compared to placebo64, leading to the withdrawal of the drug from the market. 
 
 Orlistat 
 Following the withdrawal of (dex)fenfluramine, rimonabant and sibutramine, orlistat, 
which acts via a peripheral rather than central mechanism, remains the only approved anti-
obesity drug for long-term therapy in most countries. Orlistat, a gastrointestinal lipase 
inhibitor, has been evaluated in combination with a mildly reduced-calorie reduced-fat diet in 
overweight/obese patients with49 or without T2DM65. Orlistat (120 mg 3x/day) has proven its 
efficacy and tolerability in 6-12-month placebo-controlled RCTs in overweight/obese patients 
with various background therapies (see references in Table 2). Orlistat is a useful adjunctive 
treatment for producing weight loss and reduction in waist circumference and improving 
glycaemic control, β-cell function and insulin resistance indices, serum lipid levels, 
inflammatory markers, and in some trials, blood pressure. More orlistat- than placebo-treated 
patients improved from diabetic status to normal or impaired glucose tolerance. In a 4-year 
RCT, orlistat plus lifestyle changes produced slightly greater weight loss and resulted in a 
greater reduction in the incidence of T2DM (hazard ratio : 0.627, 95% CI 0.455–0.863; 
P=0.0032) in obese patients, compared with lifestyle changes alone. The preventive effect 
was essentially explained by the difference in subjects with impaired glucose tolerance66. 
Orlistat tolerance profile is acceptable although mild to moderate, most often transient, 
gastrointestinal events were reported.  
A retrospective analysis of pooled data suggested that orlistat improves glycaemic 
control more than would be predicted by weight loss alone67, in agreement with an indirect 
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comparison between orlistat and sibutramine57. Postulated mechanisms underlying this 
intrinsinc effect of orlistat on glucose control include improvement of insulin sensitivity, 
incomplete digestion of dietary fat, reduction of postprandial plasma non-esterified fatty 
acids, decreased visceral adipose tissue, and partial stimulation of GLP-1 secretion67. 
 
  Phentermine plus topiramate 
Topiramate, a sulfamate-substituted monosaccharide whose complex mechanism of 
action remains poorly  known, is approved as a treatment for migraine headaches, bipolar 
disease and seizure disorders. Although known to facilitate weight loss, an effect confirmed in 
RCTs in obese individuals68, topiramate monotherapy does not have a regulatory indication as 
an anti-obesity agent. Nevertheless, RCTs investigated topiramate (96 mg or 192 mg/day) in 
overweight/obese patients with T2DM (see reference in Table 3). Topiramate significantly 
reduced bodyweight and HbA1c in a dose-dependent manner, with a HbA1c reduction more 
than predicted from observed weight loss. However, topiramate 96 mg twice daily did not 
significantly increase insulin-stimulated glucose uptake, despite reductions in body weight, 
body fat and HbA1c levels69. Using the new controlled release formulation of topiramate ER 
(extended release [ER]) confirmed significant reductions in bodyweight and HbA1c in 
patients with T2DM (Table 3). However, the central nervous system and psychiatric adverse 
event profile of topiramate makes it unsuitable for the treatment of obesity and T2DM as 
monotherapy. 
Phentermine, a well known sympathomimetic amine acting as stimulant and appetite-
suppressant, was combined with topiramate ER as a fixed-dose combination (FDC) to further 
decrease appetite and increase satiety70. Several RCTs demonstrated it to be effective in 
losing weight and improving adiposopathy-associated metabolic diseases, including 
dysglycaemia71. The efficacy and safety of two doses of phentermine plus topiramate ER 
combination (7.5 plus 46 mg and 15 plus 92 mg) as an adjunct to lifestyle for weight loss and 
metabolic risk reduction were assessed in individuals who were overweight/obese, with two 
or more risk factors (hypertension, dyslipidaemia, diabetes or prediabetes, or 
abdominal obesity)72. At 56 weeks, changes in bodyweight were significantly greater with 
both combinations than with placebo. The higher dose was associated with a slight increase in 
depression- and anxiety-related adverse events72. In a subanalysis, metformin-treated T2DM 
patients reported greater weight loss and reductions in HbA1c with both doses of phentermine 
plus topiramate than with placebo (Table 3). Among individuals without diabetes at baseline, 
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fewer patients progressed to T2DM ; the relative risk (vs placebo) was 0.78 (95% CI 0.40–
1.50) with phentermine 7.5 mg plus topiramate 46 mg, and 0.47 (95% CI 0.25–0.88) with 
phentermine 15 mg plus topiramate 92 mg. These positive results were confirmed in a two-
year extension period (see reference in Table 3). In subjects with T2DM at baseline, HbA1c 
did not change in the placebo group (despite net increases in glucose-lowering medications), 
whereas treatment with low and high strengths of the FDC led to significant HbA1c 
reductions (Table 3). In subjects without T2DM at baseline, the favourable effects of weight 
loss on insulin sensitivity and glycaemia were associated with decreased progression to 
T2DM (-54%, P=0.1514 with the lower dosage and -76%, P=0.0078 with the higher dosage) 
after 104 weeks. Finally, in overweight subjects with prediabetes and/or metabolic syndrome, 
phentermine plus topiramate ER produced significant weight loss and markedly reduced 
progression to T2DM, accompanied by improvements in multiple cardiometabolic disease 
risk factors73.  
 
  Lorcaserin 
Oral lorcaserin, a selective serotonin 5-HT2C receptor agonist resulting in decreased 
food intake and increased satiety, is indicated in the US as an adjunct to diet and exercise in 
the chronic weight management of obese  (BMI ≥30 kg/m²) adults, or overweight (BMI ≥27 
kg/m²)  adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, 
T2DM)74.  In a systematic review and meta-analysis of one-year RCTs in obese adults, weight 
loss of 3.23 kg was observed with lorcaserin (10 mg once or twice daily) compared with 
placebo75. In comparison to placebo, lorcaserin decreased waist circumference, blood 
pressure, cholesterol and triglycerides, without affecting heart rate. Adverse events were 
headache, nausea and dizziness74, 75.  
The 1-year BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity and 
Overweight Management in Diabetes Mellitus) study evaluated lorcaserin in T2DM patients 
treated with metformin, a sulfonylurea or both. Weight loss was amplified, more patients lost 
≥5% bodyweight, while HbA1c and fasting glucose reductions were greater with the two 
doses of lorcaserin (10 mg once or twice daily) than with placebo (see reference in Table 3). 
Slightly more patients taking lorcaserin than placebo decreased the overall use of oral 
antidiabetic medications while fewer patients taking lorcaserin increased the total daily dose 
of glucose-lowering agents. Insulin resistance index was more markedly reduced with 
lorcaserin compared to placebo, but no significant between-group differences were observed 
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regarding lipid profile, blood pressure or inflammatory markers. Symptomatic hypoglycaemia 
occurred slightly more frequently with lorcaserin than with placebo.  
 
Antidiabetic agents with positive effects on obesity  
Pramlintide 
Pramlintide is an analogue of the pancreatic hormone amylin, which is relatively 
deficient in patients with T2DM37. Through mechanisms similar to those of 
amylin, pramlintide (120-240 microg 3 times daily) improves overall glycaemic control and 
reduces bodyweight in patients with T2DM (Figure 3, Table 4). Besides reducing postprandial 
glucose levels, pramlintide treatment is also associated with improvements in markers of 
oxidative stress and CV risk. Pramlintide has been shown to increase satiety and, therefore, 
decrease caloric intake via a central mechanism37. It is generally well tolerated, with the most 
frequent treatment-emergent adverse event being transient nausea. 
Preliminary trials assessing the use of pramlintide for weight loss in obese patients 
without diabetes have demonstrated weight loss of up to 8 kg after 1 year. However, current 
trials were limited by inconsistent study design, dosing, and patient population76. Newer 
research is focusing on weight loss effects with a combined peptide approach in obese 
individuals (see below)37, 77.   
 
  GLP-1 receptor agonists and DPP-4 inhibitors  
Incretin-based therapies exploit the insulinotropic actions of GIP (glucose-dependent 
insulinotropic polypeptide) and GLP-1 for the treatment of T2DM (Figure 3, Table 4). They 
include GLP-1 receptor agonists (GLP-1RAs) and inhibitors of dipeptidyl peptidase-4 (DPP-
4), the enzyme that inactivates these two incretin hormones in the body38. Weight neutrality of 
DPP-4 inhibitors (also called gliptins) while improving glucose control78   may be an 
advantage in the management of overweight/obese patients with T2DM compared with other 
glucose-lowering agents known to promote weight gain (see above)21. Furthermore, these new 
compounds do not expose patients to hypoglycaemia (except when added to insulin or 
sulphonylureas)78 and may also exert favourable effects on various CV risk factors79. Similar 
positive effects are observed with GLP-1RAs80 , with the add-on value of promoting weight 
loss in obese patients with T2DM22. Furthermore, GLP-1RA effects on bodyweight are also 
apparent in non-diabetic obese individuals, offering a potential for use in the treatment 
of obesity81. 
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According to a systematic review of RCTs in overweight/obese patients with or 
without T2DM, treatment with GLP-1RAs (as monotherapy or combination therapy : 
exenatide twice daily, exenatide once weekly, or liraglutide once daily) results in greater 
weight loss than control groups (placebo, oral antidiabetic drugs, or insulin). Weight loss was 
recorded in the GLP-1RA groups for patients with diabetes (-2.8 kg, 95% CI -3.4 to -2.3) and 
without diabetes (-3.2 kg, 95% CI -4.3 to -2.1). In T2DM patients, GLP-1RAs had beneficial 
effects on blood pressure, plasma cholesterol, and glycaemic control (see reference in Table 
4).  GLP-1RAs were associated with nausea, diarrhoea, and vomiting, a slight increase in 
pulse rate, but not with hypoglycaemia. In a post-hoc analysis of 26-week data from seven 
RCTs assessing liraglutide (1.2-1.8 mg once daily) in T2DM, liraglutide-treated subjects 
experienced additional HbA1c reduction beyond that which induced by weight loss82.   
In patients with T2DM not well controlled on oral glucose-lowering therapies (mainly 
metformin and/or sulfonylurea) and compared with insulin glargine83, the addition of GLP-
1RAs showed almost similar (or better) blood glucose control but with a lower incidence of 
hypoglycaemia and less weight gain (conversely a significant weight loss was recorded). The 
combination of a GLP-1RA (mainly targeting postprandial hyperglycaemia) and basal insulin 
(mainly targeting fasting hyperglycaemia) may also be highly effective for optimal glucose 
control, while limiting weight gain, an adverse effect typically associated with insulin therapy 
in patients with T2DM84.  
Liraglutide85, 86 appears also to have promising effects on bodyweight in 
overweight/obese adults without T2DM. Monotherapy with liraglutide at a higher dose of 2.4-
3.0 mg once a day induced significant and sustained weight loss, improved certain obesity-
related risk factors (especially blood pressure), and reduced the incidence of prediabetes and 
metabolic syndrome over 1-2 years85, 86. Of interest, results were more favourable with 
liraglutide than with orlistat (120 mg three times a day orally) used as an active comparator.  
Several studies investigated whether weight loss with GLP-1RAs corresponds to fat 
loss and which mechanisms might be implicated (see references in Table 5). Overall, studies 
demonstrated significant reductions in waist circumference, total fat and visceral fat, 
proportional to weight loss; this effect resulted from decreased appetite and reduced  energy 
intake (with some changes in food preference), with almost no or only a slight increase in 
energy expenditure.  
Finally, GLP-1RAs were shown to improve various CV risk factors in 
overweight/obese T2DM patients, especially blood pressure, postprandial lipid profile, 
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endothelial dysfunction, inflammatory markers and oxidative stress80.  All these pleiotropic 
effects may lead to improvement in CV prognosis, although this hypothesis remained to be 
confirmed in ongoing large prospective RCTs80. 
 
  SGLT-2 inhibitors 
SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) increase glucose 
excretion, independent of insulin secretion or action, by inhibiting the renal reabsorption of 
glucose87. Dapagliflozin (5 or 10 mg) has been approved in Europe for the treatment of 
T2DM as an adjunct to diet and exercise, in combination with other glucose-lowering 
medicinal products, including insulin, and as a monotherapy for metformin-intolerant 
patients88 while canagliflozin was approved by the US Food and Drug Administration in April 
2013 and is undergoing evaluation by the European Medicines Agency89.  Other SGLT-2 
inhibitors (especially empagliflozin) are currently in late phase of clinical development.  
In patients with T2DM, SGLT-2 inhibitors reduced HbA1c (-0.5% to -1.5%) when 
used as either monotherapy or combined therapy with any other glucose-lowering agent, 
including insulin, with a weight loss of up to 3 kg (Figure 3)  and a low incidence of 
hypoglycaemia. Cardiometabolic benefits included a reduction in systolic blood pressure and 
triglycerides (see reference in Table 4). Because of side effects (urinary tract and genital 
infections), a potential risk of dehydration (elderly patients on diuretics) and a reduced 
glucose-lowering activity in subjects with renal impairment, appropriate patient selection and 
close monitoring will be important. Further clinical studies should demonstrate the effect of 
SGLT-2 inhibitors on diabetic complications and CV events as well as their long-term 
tolerability/safety profile.  
So far, SGLT-2 inhibitors are the only oral glucose-lowering agents also promoting 
significant weight loss23. Dapagliflozin induced weight loss, predominantly by reducing fat 
mass, visceral and subcutaneous adipose tissue in patients with T2DM inadequately 
controlled with metformin90. Experimental data in rodents suggested, however, that the 
persistent urinary glucose excretion induced by dapagliflozin was accompanied by 
compensatory hyperphagia91. These animal observations are in agreement with findings in 
humans showing a lower weight loss than that predicted by the recurrent waste of calorie 
through sustained increased glucosuria. Therefore, gliflozin-induced weight loss might also 
require dietary intervention or other adjunct therapies limiting food intake.  
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 The future for pharmacology of T2D and obesity 
 Novel pharmacological therapies are currently under investigation as potential 
treatments for obesity and T2DM50.  There are two main avenues of investigation: the first 
targets the central nervous system to reduce food intake (with drugs including naltrexone plus 
bupropion, tesofensine and zonisamide) but again with the risk of frequent adverse events92; 
the second is more innovative and targets complex interrelated hormonal pathways (brain, 
gut, adipose tissue) involved in weight regulation and glucose homeostasis (Figure 1)93, 94. 
 
Naltrexone sustained release plus bupropion sustained release  
The efficacy of current centrally-acting obesity pharmacotherapies is limited by 
compensatory mechanisms that mitigate weight loss and by potential side effects, paving the 
route for combined therapies. Opioid receptor antagonism (naltrexone) plus pro-
opiomelanocortin activation (bupropion) causes greater weight loss than monotherapy with 
either agent or placebo95, an effect confirmed in overweight/obese patients with 
comorbid T2DM, hypertension or hyperlipidaemia96, 97. Overall, placebo-subtracted mean 
weight loss averaged 4.7% (range 3.2-5.2%) with naltrexone/bupropion after 1 year, with a 
higher proportion of patients achieving ≥5-10% weight loss and improvement of waist 
circumference, triglycerides, high-density lipoprotein, fasting insulin, and insulin resistance 
compared with placebo. Reductions in body fat mass and visceral adipose tissue were 
proportional with weight loss98. In patients with T2DM, naltrexone/bupropion therapy 
significantly decreased HbA1c 0.5% more than placebo (see reference in Table 3). Because 
systolic blood pressure and pulse rate were higher compared with placebo, further studies are 
necessary to determine the effect of naltrexone/bupropion on CV outcomes. It is not approved 
as an anti-obesity therapy yet99. 
 
Leptin and leptin-related synthetic peptide analogues 
Leptin not only controls food intake and energy expenditure, but also modulates the 
insulin-glucose axis36. Consequently, leptin replacement therapy raised hope in obesity and 
T2DM100. Unfortunately, results with recombinant human leptin were rather disappointing, 
especially in overweight/obese patients with T2DM101. Metreleptin, an analogue of human 
leptin, improved insulin sensitivity, hypertriglyceridaemia and hyperglycaemia in patients 
with lipodystrophy102. In obese patients with T2DM, however, metreleptin did not alter body 
weight or circulating inflammatory markers and reduced HbA1c only marginally103. New 
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approaches in the development of anti-obesity and anti-diabetes pharmacophores are now 
focused on utilizing leptin-related synthetic peptides as leptin receptor antagonists or leptin-
related synthetic peptide analogues or mimetics104.  
 
Peptide hormone combination therapies 
Experimental data suggest that leptin and amylin, two hormones involved in satiation 
control (see above), have additive effects105. In a proof-of-concept RCT in overweight/obese 
subjects, combination treatment with pramlintide/metreleptin led to significantly, early and 
sustained, greater weight loss than treatment with pramlintide or metreleptin alone. Although 
pramlintide/metreleptin combination was promising as novel, integrated neurohormonal 
approach to obesity pharmacotherapy with or without T2DM106, 107, the latest RCT was 
recently stopped due to safety concerns108. 
Finally, instead of using two or more agonists for the treatment of obesity and T2DM, 
another promising option may be the use of single co-agonists. As examples, GLP-1-glucagon 
and GLP-1-amylin co-agonists may be of potential interest109. Although substantial progress 
has been achieved in preclinical studies, the putative success and safety of co-
agonist therapy for the treatment of patients with obesity and T2DM remains uncertain and 
requires extensive additional clinical validation110. Another potential future option is a SGLT-
2 inhibitor/GLP1-RA combination in an attempt to weaken the compensatory “overeating” 




The management of the obese diabetic patient remains challenging, but, in any case, 
weight reduction should be considered as a key objective. Lifestyle intervention to lose 
weight is recommended in most T2DM patients to improve glycaemic control and reduce 
associated risk factors for complications. Even modest weight loss can significantly improve 
glucose homeostasis and lessen cardiometabolic risk factors, although achieving and 
especially maintaining 5-10% weight reduction remains difficult for many patients, and these 
surrogate endpoints are not always strengthened by hard outcome data. There is a growing 
concern that the weight gain induced by some diabetes medications diminishes their clinical 
benefits. New glucose-lowering agents (incretin-based therapies, SGLT-2 inhibitors) are 
associated with some weight reduction and improvement of various CV risk factors. 
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However, the long-term benefit-risk profile of these new compounds remains to be 
determined in large prospective studies. Finally, the place of anti-obesity agents in the 
management of overweight/obese patients with T2DM was limited by rather poor efficacy 
and safety concern. A better understanding of weight-regulating mechanisms has led to the 
identification of new targets for anti-obesity agents. Especially, peptide hormones control 
body weight and glucose homeostasis by engaging peripheral and central metabolic signalling 
pathways responsible for the maintenance of body weight and euglycaemia. Notably, 
therapeutic attempts to normalize body weight and glycaemia with single agents alone have 
generally been disappointing paving the route for using combined therapies in the future.   
Individualized therapy in the management patients with T2DM will become 
increasingly important with (and perhaps a consequence of ) the increasing number of drugs 
available and the presence of obesity may certainly influence the physician’s choice of the 
best pharmacological approach. 
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Figure 1 : Illustration of the complex pathophysiology of obesity and T2DM, involving 
genetics, epigenetics and environment  burdens interfering with various target organs that are 
interconnected via complex hormonal pathways  (↔) . GLP-1 : glucagon-like peptide-1. GIP : 
glucose-dependent insulinotropic polypeptide. NEFA : non esterified fatty acids. 
 
Figure 2 : Main mechanisms controlling bodyweight (upper panel A) and blood glucose 
(lower panel B) and crucial role of lifestyle (before considering pharmacological interventions 
: see figure 2). Bodyweight changes influence glucose control while glucose control may 
influence bodyweight changes in patients with type 2 diabetes. Besides lifestyle, genetics may 
also play a role in controlling appetite and energy expenditure (resting metabolic rate, 
thermogenesis, energy metabolism).  
 
 
Figure 3 : Multiple pharmacological approaches used to control hyperglycaemia in type 2 
diabetes with special focus on drug’s effect on bodyweight. (*) Modest effect. GLP-1 RA : 
glucagon-like peptide-1 receptor agonist. DPP-4 : dipeptidyl peptidase-4 inhibitor. SGLT-2 :  
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Table 1 : Mean effects of sibutramine and rimonabant on bodyweight, HbA1c, fasting plasma glucose, blood pressure and total cholesterol in placebo-
controlled trials in overweight/obese patients with T2DM. Only trials that randomised at least 50 patients per arm with a follow-up of at least 16 weeks were 
considered (no such trials were reported with fenfluramine./dexfenfluramine). * References available in appendix. $ p-value < 0.05 compared with placebo or 
control.  [A: without p values or CIs, it is not possible for the reader to determine which trials showed a real difference between groups. Thus, for 
columns highlighted here and in other tables, please note which differences were significant, perhaps just by applying a symbol. I added as example 

































Kaukua et al 
2004111 
Diet 52 Pbo : 122 
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SU 26 Pbo : 65 



















McNulty et al 
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Metformin 52 Pbo : 64 
Sibu 15 mg : 68 
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2000114 
Met/SU 24 Pbo : 86 
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Scheen et al 
2006116 
Met or SU 52 Pbo : 348 
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SU : sulphonylurea. Met : metformin. Pbo : placebo. Sibu : sibutramine.  Rimo : rimonabant. BMI : body mass index. BW : body weight. HbA1c : glycated 
haemoglobin. FPG : fasting plasma glucose. SBP : systolic blood pressure. DBP : diastolic blood pressure. Δ : change versus baseline. NA : not available. 
Table 2 : Mean effects of orlistat (120 mg 3x/day) on bodyweight, HbA1c, fasting plasma glucose, blood pressure and total cholesterol in placebo-controlled 
trials in overweight/obese patients with T2DM. Note that orlistat treatment reduced the requirement for anti-diabetic medication more than placebo. Only trials 
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2005122 
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Met + SU 
52 P : 109
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+ 0.08 
- 0.30 
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SU : sulphonylurea. Met : metformin. P : placebo. O : orlistat. BMI : body mass index. BW : body weight. HbA1c : glycated haemoglobin. FPG : fasting 
plasma glucose. SBP : systolic blood pressure. DBP : diastolic blood pressure. Δ : change versus baseline. NA : not available. 
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Table 3 : Mean effects of topiramate, topiramate/phentermine, lorcaserin and naltrexone/bupropion on bodyweight, HbA1c, fasting plasma glucose, blood 
pressure and total cholesterol with T2DM in placebo-controlled trials in overweight/obese patients. Only trials that randomised at least 50 patients per arm 

































Stenlof et al 
2007124 
Diet 40 Pbo : 78 
Topi 96 mg : 74 
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- 6.3/- 3.3 




Toplak et al 
2007125 
Metformin 24 Pbo : 208 
Topi 96 mg : 219 
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et al 2007126 
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± Met 
16 Pbo : 57 
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- 10.2/- 5.3 
- 0.08 
- 0.32 
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Topi 46 mg +  
Phen 75 mg : 67 
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Lorca 2 x 10 mg : 251 
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- 0.8/- 1.1 















Pbo : 159 





























(*) Change expressed in % of initial body weight instead of kg. (**) Analysis in a subgroup of patients with T2DM 
SU : sulphonylurea. Met : metformin. OAD : oral antidiabetic drug. Pbo : placebo. Topi : topiramate. Phen : phentermine. Lorca : lorcaserin. Nal/Bup : 
naltrexone/bupropion. BMI : body mass index. BW : body weight. HbA1c : glycated haemoglobin. FPG : fasting plasma glucose. SBP : systolic blood 
pressure. DBP : diastolic blood pressure. Δ : change versus baseline. NA : not available. 
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Table 4 : Meta-analyses of randomised controlled trials with pramlintide, GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors in patients with 
T2DM : Mean effects on bodyweight, HbA1c, fasting plasma glucose, blood pressure and total cholesterol. Results are expressed as weighted mean 
differences versus placebo (95% confidence intervals). Results reported with the anti-obesity agent orlistat (the only anti-obesity drug available worldwide) 















∆ SBP  
mmHg  





Anti-obesity agent         
ORLISTAT 
Norris et al 
200549 
4 904 - 2.64 
(- 3.17,  
- 2.11) 
- 0.38 
(- 0.51,  
- 0.25) 
- 0.86 
(- 1.32,  
- 0.40) 
- 1.11 
(- 2.91,  
+ 0.69) 
- 1.30 





Glucose-lowering agents         
PRAMLINTIDE 
Sing-Franco et al 
2011130 
5 930 - 2.57 
(- 3.44,  
- 1.70) 
- 0.33 
(- 0.51,  
- 0.14) 
- 0.35 
(- 1.39,  
+ 0.68) 
NA NA NA 
GLP-1RAs 








(- 3.59,  
- 2.22) 
- 0.63 
(- 0.80,  
- 0.46) 
- 1.32 
(- 1.35, - 
1.29) 
- 3.57 
(- 5.49,  
- 1.66) 
- 1.38 






Kim et al 2013132 
 
 













































(- 0.46,  
- 0.10) 
SGLT-2 INHIBITORS 13 4063 - 1.17 (*) - 0.52 - 1.02 - 4.08 - 1.16 NA 
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(- 4.91,  
- 3.24) 
(- 1.67,  
- 0.66) 
 (*) Change expressed as percentage of initial body mass index 
GLP-1 RA : glucagon-like peptide-1 receptor agonist. DPP-4 : dipeptidyl peptidase-4 inhibitor. SGLT-2 :  sodium glucose cotransporter-2. BW : body weight. 
HbA1c : glycated haemoglobin. FPG : fasting plasma glucose. SBP : systolic blood pressure. DBP : diastolic blood pressure. NA : not available. 
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Table 5 : Mean effects of GLP-1 receptor agonists on weight loss, reduction in total fat mass and visceral adipose tissue, appetite/energy intake and energy 
expenditure, vs background therapy [A:OK?]. Mean results reported in completers. All controlled trials of potential interest, whatever the number of 

































Bunck et al 
2010135 
Metformin Exe 2x10µg 52 69 NA -3.9 -2.4 -13 NA NA 
Bradley et al 
2012136 
No diabetes Exe 2x10 µg 14 45 NA -2.0 -1.3 NA NA No change 
Jendle et al 
2009137 
Metformin Lira 1.2 mg 















Jendle et al 
2009137 
Diet Lira 1.2 mg 













Inoue et al 
2011138 
OAD/insulin Lira 0.9 mg 26 29 -1.1 -8.2 NA NA Reduced NA 
Suzuki et al 
2013139 
OAD/insulin  Lira 0.9 mg 26 46 -0.3 -2.0 NA -6 NA NA 
Horowitz et al 
2012140 
Diet/OAD Lira 1.8 mg 4 38 NA -1.3 NA NA Reduced +7.6% 
Flint et al 
2013141 
Diet/OAD Lira 0.6-1.8 
mg 
3 18 NA -0.55 NA NA Reduced NA 
OAD : oral antidiabetic drug. GLP-1 RA : GLP-1 receptor agonist. Exe : exenatide. Lira : liraglutide. HbA1c : glycated haemoglobin. Δ : change versus 
baseline. NA : not available. 
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